Nancy Whiting

894 total citations
18 papers, 683 citations indexed

About

Nancy Whiting is a scholar working on Oncology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Nancy Whiting has authored 18 papers receiving a total of 683 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Nancy Whiting's work include Lymphoma Diagnosis and Treatment (8 papers), CAR-T cell therapy research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Nancy Whiting is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), CAR-T cell therapy research (6 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Nancy Whiting collaborates with scholars based in United States and Switzerland. Nancy Whiting's co-authors include Jonathan G. Drachman, Andres Forero‐Torres, Ranjana H. Advani, Richard R. Furman, Joseph D. Rosenblatt, Anas Younes, Hong Ren, Stephen M. Ansell, Nikhil C. Munshi and Rubén Niesvizky and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Nancy Whiting

18 papers receiving 665 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nancy Whiting United States	10	463	283	230	125	123	18	683
Eric D. Mortenson United States	6	489 1.1×	303 1.1×	213 0.9×	115 0.9×	25 0.2×	8	656
Joy Knight United States	8	288 0.6×	154 0.5×	113 0.5×	247 2.0×	290 2.4×	13	633
Patricia McElroy United States	13	340 0.7×	175 0.6×	118 0.5×	151 1.2×	30 0.2×	25	761
Aruna Gowda United States	8	231 0.5×	186 0.7×	119 0.5×	87 0.7×	263 2.1×	15	516
Beata Holkova United States	13	307 0.7×	87 0.3×	49 0.2×	222 1.8×	297 2.4×	48	634
M Andreeff United States	8	135 0.3×	99 0.3×	64 0.3×	90 0.7×	137 1.1×	14	373
Huimin Meng China	14	357 0.8×	265 0.9×	86 0.4×	209 1.7×	24 0.2×	34	582
Benedetta Urbini Italy	10	121 0.3×	185 0.7×	43 0.2×	93 0.7×	37 0.3×	23	462
Gabriela Mladonická Pavlasová Czechia	6	110 0.2×	179 0.6×	53 0.2×	128 1.0×	134 1.1×	6	460

Countries citing papers authored by Nancy Whiting

Since Specialization

Citations

This map shows the geographic impact of Nancy Whiting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Whiting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Whiting more than expected).

Fields of papers citing papers by Nancy Whiting

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Whiting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Whiting. The network helps show where Nancy Whiting may publish in the future.

Co-authorship network of co-authors of Nancy Whiting

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy Whiting. A scholar is included among the top collaborators of Nancy Whiting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy Whiting. Nancy Whiting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Sharman, Jeffrey P., Jennifer J. Wheler, Lawrence H. Einhorn, et al.. (2019). A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Investigational New Drugs. 37(4). 738–747. 12 indexed citations

Coveler, Andrew L., Andrew H. Ko, Daniel V.T. Catenacci, et al.. (2016). A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Investigational New Drugs. 34(3). 319–328. 21 indexed citations

Sussman, Django, Leia M. Smith, Martha E. Anderson, et al.. (2014). SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. Molecular Cancer Therapeutics. 13(12). 2991–3000. 104 indexed citations

Vos, Sven de, Andres Forero‐Torres, Stephen M. Ansell, et al.. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of Hematology & Oncology. 7(1). 44–44. 77 indexed citations

Tannir, Nizar M., Andres Forero‐Torres, Radhakrishnan Ramchandren, et al.. (2014). Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Investigational New Drugs. 32(6). 1246–1257. 97 indexed citations

Moss, Aaron M., Jean Gudas, Tina Albertson, Nancy Whiting, & Che‐Leung Law. (2014). Abstract 104: Preclinical microPET/CT imaging of 89Zr-Df-SGN-35 in mice bearing xenografted CD30 expressing and non-expressing tumors. Cancer Research. 74(19_Supplement). 104–104. 5 indexed citations

Coveler, Andrew L., Daniel D. Von Hoff, Andrew H. Ko, et al.. (2013). A phase I study of ASG-5ME, a novel antibody-drug conjugate, in pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 31(4_suppl). 176–176. 7 indexed citations

Thompson, John A., Andres Forero, Elisabeth I. Heath, et al.. (2013). SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma.. Journal of Clinical Oncology. 31(6_suppl). 368–368. 4 indexed citations

Sussman, Django, Leia M. Smith, Martha E. Anderson, et al.. (2013). Abstract 3962: SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer.. Cancer Research. 73(8_Supplement). 3962–3962. 4 indexed citations

10.

Forero‐Torres, Andres, Nancy L. Bartlett, Anne Beaven, et al.. (2012). Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 54(2). 277–283. 34 indexed citations

11.

Thompson, John A., Elisabeth I. Heath, Stephen M. Ansell, et al.. (2011). The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study.. Journal of Clinical Oncology. 29(15_suppl). 3071–3071. 12 indexed citations

12.

Hussein, M. A., James R. Berenson, Rubén Niesvizky, et al.. (2010). A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 95(5). 845–848. 112 indexed citations

13.

Dornan, David, Bart Burington, Yue Peng, et al.. (2009). CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.. Blood. 114(22). 2721–2721. 1 indexed citations

14.

Forero‐Torres, Andres, Nancy L. Bartlett, Sunita D. Nasta, et al.. (2009). A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.. Blood. 114(22). 586–586. 5 indexed citations

15.

Advani, Ranjana H., Andres Forero‐Torres, Richard R. Furman, et al.. (2009). Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 27(26). 4371–4377. 151 indexed citations

16.

Agura, Edward, Rubén Niesvizky, Jeffrey Matous, et al.. (2009). Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.. Blood. 114(22). 2870–2870. 28 indexed citations

17.

Advani, Ranjana H., Bart Burington, Sven de Vos, et al.. (2009). Evaluation of a gene signature to predict single agent dacetuzumab (SGN-40) activity in patients with DLBCL. Journal of Clinical Oncology. 27(15_suppl). 11063–11063. 1 indexed citations

18.

Advani, Ranjana H., Sven de Vos, Stephen M. Ansell, et al.. (2008). A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma.. Blood. 112(11). 1000–1000. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact